Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β<ce:inf loc=post>2</ce:inf> agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

@article{Wenzel2016DupilumabEA,
  title={Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β<ce:inf loc=post>2</ce:inf> agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial},
  author={Sally Wenzel and Mario Castro and Jonathan Corren and Jorge Fernando Maspero and Ariel Teper},
  journal={The Lancet},
  year={2016},
  volume={388},
  pages={31-44}
}
BACKGROUND Dupilumab, a fully human anti-interleukin-4 receptor α monoclonal antibody, inhibits interleukin-4 and interleukin-13 signalling, key drivers of type-2-mediated inflammation. Adults with uncontrolled persistent asthma who are receiving medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist require additional treatment options as add-on therapy. We aimed to assess the efficacy and safety of dupilumab as add-on therapy in patients with uncontrolled persistent asthma… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 105 CITATIONS

FILTER CITATIONS BY YEAR

2016
2019

CITATION STATISTICS

  • 11 Highly Influenced Citations

  • Averaged 33 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 30 REFERENCES

ammation in asthma

  • NA Gandhi, BL Bennett, NM Graham, G Pirozzi, N Stahl, GD. Yancopoulos
  • Nat Rev Immunol
  • 2015

Similar Papers

Loading similar papers…